BioVie Inc., a clinical stage biopharmaceutical firm headquartered in Carson City, Nevada, is making strides in the discovery, development, and commercialization of drugs geared towards the treatment of chronic debilitating conditions in the United States. The company's product pipeline boasts BIV201, which has completed its Phase IIa clinical trial and could be a promising treatment option for ascites brought on by chronic liver cirrhosis. Additionally, NE3107, a selective inflammatory extracellular single-regulated kinase inhibitor, is currently undergoing Phase III clinical trials for the treatment of Alzheimer's disease in mild to moderate patients while concurrently undergoing Phase 2 clinical trials for treating Parkinson's disease. Apart from these products, BioVie Inc. is also working on NE3107, which is still in its pre-clinical stage but shows great promise for treating prostate cancer and multiple myeloma. Formerly known as NanoAntibiotics, Inc., the company changed its name in July 2016 and was incorporated in 2013.
BioVie Inc.'s ticker is BIVI
The company's shares trade on the NASDAQ stock exchange
They are based in Carson City, Nevada
There are 1-10 employees working at BioVie Inc.
It is https://bioviepharma.com/
BioVie Inc. is in the Healthcare sector
BioVie Inc. is in the Biotechnology industry
The following five companies are BioVie Inc.'s industry peers:
- Checkpoint Therapeutics, Inc.